Chuck Love

Medicare Advantage Plans & ACOs have seen their costs grow in COPD by 53% since 2010, because of high admission and readmission rates (22%). More expensive inhalers are not the only solution to curb this trend. Pulmonary Rehabilitation (PR) is a comprehensive intervention including endurance training, behaviour change and patient education which is proven to significantly improve COPD outcomes. Pulmonary Rehab has been around for decades and recommended by global and national guidelines, but less than 2% of COPD patients get access because there is one PR center for every 43,000 COPD patients in the US. BreatheSuite is a fully virtual Pulmonary Rehabilitation program designed to reduce COPD readmissions and medical expenses. BreatheSuite’s fully virtual program is built on clinically validated protocols, proven to save $5,700 per enrolled patient annually.

Neptune Medical is a venture capital funded medical device start-up, located in the Silicon Valley town of Burlingame. We develop, manufacture, and commercialize high-volume, high clinical utility medical devices initially commercialized for gastroenterology, see our website below. Our patent-pending technology is foundational and will have a broad impact across multiple additional clinical areas, including including GI, cardiovascular, pulmonary, and neuro. Our Triton Medical Robotics division is developing flexible robotic systems that address enormous unmet needs across multiple major medical indications. Our products incorporate unique Dynamic Rigidization™ technology that instantly toggles thin-walled tubes- such as overtubes, catheters or cannulae - between flexible and rigid states. This novel technology creates unprecedented opportunities for significantly enhanced access and control deep within the body. Neptune Medical currently has ~50 full time employees across all divisions, including a core team of serially successful medical device entrepreneurs. The company has raised over $30M in capital from a diversified investor base, including venture capital, private equity, and industry insider and clinician angel investors.

Medicare Advantage Plans & ACOs have seen their costs grow in COPD by 53% since 2010, because of high admission and readmission rates (22%). More expensive inhalers are not the only solution to curb this trend. Pulmonary Rehabilitation (PR) is a comprehensive intervention including endurance training, behaviour change and patient education which is proven to significantly improve COPD outcomes. Pulmonary Rehab has been around for decades and recommended by global and national guidelines, but less than 2% of COPD patients get access because there is one PR center for every 43,000 COPD patients in the US. BreatheSuite is a fully virtual Pulmonary Rehabilitation program designed to reduce COPD readmissions and medical expenses. BreatheSuite’s fully virtual program is built on clinically validated protocols, proven to save $5,700 per enrolled patient annually.

Neptune Medical is a venture capital funded medical device start-up, located in the Silicon Valley town of Burlingame. We develop, manufacture, and commercialize high-volume, high clinical utility medical devices initially commercialized for gastroenterology, see our website below. Our patent-pending technology is foundational and will have a broad impact across multiple additional clinical areas, including including GI, cardiovascular, pulmonary, and neuro. Our Triton Medical Robotics division is developing flexible robotic systems that address enormous unmet needs across multiple major medical indications. Our products incorporate unique Dynamic Rigidization™ technology that instantly toggles thin-walled tubes- such as overtubes, catheters or cannulae - between flexible and rigid states. This novel technology creates unprecedented opportunities for significantly enhanced access and control deep within the body. Neptune Medical currently has ~50 full time employees across all divisions, including a core team of serially successful medical device entrepreneurs. The company has raised over $30M in capital from a diversified investor base, including venture capital, private equity, and industry insider and clinician angel investors.